Table 3 Characteristics of the study population, according to the occurrence or not of overall new PCI (for restenosis and de novo IHD) (n = 54)

Age (years), median [IQR]

59.5 [58–60.7]

60.5 [57.7–63]

Sex, no. (%)

 M

6 (75)

40 (87)

 F

2 (25)

6 (13)

BMI, kg/m², median [IQR]

26.7 [24.8–28.8]

27 [25.8–28]

Blood pressure (mmHg), median [IQR]

 Systolic

125 [120–130]

130 [120–136.2]

 Diastolic

80 [72.5–80]

80 [70–80]

Hypertension, no. (%)

1 (14)

14 (30)

Smoke, no. (%)

7 (88)

36 (78)

Cholesterol (mg/dL), median [IQR]

Total

173.5 [147.5–209.7]

172.5 [146.2–189]

 HDL

44 [34.2–64.5]

42 [35–51]

 LDL

107.5 [86–123.7]

105 [70.2–119.7]

Triglycerides (mg/dL), median [IQR]

127.5 [117.2–157.7]

127 [102.7–151.5]

Glycemia (mg/dL), median [IQR]

 Baseline

95.5 [86.2–97.7]

86.5 [79.7–89.2]

0.643 [0.389–1.064]

 2 h

132 [116–136.7]

102.5 [93–121.2]

Glycated hemoglobin (%), median [IQR]

5.6 [5.5–5.7]

5.2 [5–5.4]

Insulin (µU/mL), median [IQR]

9.8 [9.1–10.1]

3.5 [2.8–4.3]

0.008 [0.000–1.183]

HOMA IR, median [IQR]

2.23 [2.1–2.5]

0.74 [0.57–0.94]

1.5*10¹¹ [2.593–8.68 * 10²¹]

Creatinine (mg/dL), median [IQR]

1 [0.85–1.1]

1 [0.87–1.1]

Hemoglobin (mg/dL), median [IQR]

14.2 [13.2–14.8]

14.3 [13.3–15.3]

Adiponectin (µg/mL), median [IQR]

8 [6.5–8.7]

12 [10–14]

0.206 [0.053–0.796]

Resistin (ng/mL), median [IQR]

13 [6–15]

6 [4–8]

TNF-alpha (ng/mL), median [IQR]

13 [7.5–20.7]

8 [7–10]

Follow-up duration (months), median [IQR]

31 [25.7–33.7]

29 [13.5–34]

Death, no. (%)

 Cardiovascular/other causes

0 (−)/−

0 (−)/1 (2)